Item 2.02 Results of Operations and Financial Condition.

On January 11, 2021, Antares Pharma, Inc. (the "Company") issued a press release regarding its full year 2020 and 2021 revenue guidance. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 7.01 Regulation FD Disclosure.

A copy of the Antares Pharma, Inc. (the "Company") updated investor presentation slides that the Company intends to use effective immediately is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information disclosed under this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.     Description

99.1        Press Release issued by Antares Pharma, Inc., dated January 11, 2021

99.2        Antares Pharma, Inc. Investor Presentation, January 2021

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses